Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MSLN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Mesothelin ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View Mesothelin Products |
| Gene Delivery | Mesothelin Full-Length ORF Lentivirus Native GPI-anchor conformation for internalization assays; ideal for stable cell line generation. |
View Mesothelin Products |
| Benchmark Ab | Anti-Mesothelin (Amatuximab Sequence) Recombinant positive control for binding & blocking studies. Chimeric IgG1. |
View Mesothelin Products |
| Validator | Mesothelin siRNA Set For knockdown verification and specificity controls. |
View Mesothelin Products |
| Related Target: MUC16 | CA125 / MUC16 Physiological binding partner of MSLN; synergistic co-targeting for ovarian cancer and peritoneal metastasis. |
View MUC16 Products |
| Related Target: PD-L1 | CD274 / PD-L1 Combination immunotherapy checkpoint; MSLN targeting synergizes with PD-1/PD-L1 blockade in mesothelioma. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species (cyno/mouse) evaluation | Human/Cynomolgus/Mouse MSLN ECD-Fc orthologs >95% purity; sequence identity verified |
| Shed antigen (SMRP) interference | High-purity soluble MSLN variants for competitive binding assays and shedding simulation |
| Internalization efficiency (ADC payload delivery) | Full-length Lentivirus stable cell lines preserving GPI-anchor topology; pH-dependent stability testing |
| Glycosylation-dependent epitope recognition | HEK293 expressed antigens preserving native mammalian post-translational modifications |
| Lack of positive controls | Clinical Benchmark Antibodies (Amatuximab Biosimilar) included with verified sequences |
| False positives / off-target specificity | Validated MSLN siRNA set for knockdown specificity checks; ortholog panel for cross-reactivity |
Live Mesothelin R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Mesothelin therapeutics is intensifying, with major players shifting focus from first-generation monoclonal antibodies to next-generation antibody-drug conjugates (ADCs), CAR-T cells, and bispecific T-cell engagers. As first-generation therapies (e.g., Amatuximab) have validated target safety, the next wave of R&D is tackling key challenges: shed antigen (soluble Mesothelin-Related Peptides, SMRP) acting as a decoy sink, solid tumor penetration barriers, and resistance mechanisms. Epitope-engineered antibodies that avoid the N-terminal shed domain, combined with checkpoint inhibitor co-administration (e.g., PD-1/PD-L1), represent the leading strategy. Pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer are the major expanding indications beyond mesothelioma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Bayer/MorphoSys (Anetumab ravtansine), BMS (BMS-986148), ImmunoGen | Mesothelioma, Pancreatic Cancer, Ovarian Cancer | Internalization & affinity kinetics (high-purity ECD-Fc for SPR/BLI; lentivirus stable cells for FACS internalization) |
| CAR-T / Cell Therapy | Novartis, CARsgen Therapeutics, NCI | PDAC, Mesothelioma, Ovarian | Stable target-cell line generation (full-length MSLN lentivirus for engineered tumor cell lines) |
| Bispecific T-cell Engager | Roche/Genentech (RG7744), Regeneron | Solid Tumors | Epitope binning & heterodimer validation (cross-reactive benchmark antibodies; ortholog protein panel) |
| Immunotoxin | NCI (LMB-100) | Mesothelioma, Pancreatic Cancer | Cytotoxicity & internalization efficiency (high-purity antigen for competition assays) |
| Tumor Vaccine | Novartis (CRS-207) | Mesothelioma | Immunogenicity assessment (high-purity protein adjuvant) |
Molecular Differentiation & Assay Strategy
To develop best-in-class MSLN therapeutics, precise molecular design is required. Key differentiators include:
- Affinity: Moderate affinity often outperforms ultra-high affinity for solid tumor penetration, avoiding the "binding site barrier."
- Epitope: Must target the juxtamembrane domain to bypass shed SMRP sink; avoid the N-terminal region.
- Internalization: ADC and immunotoxin efficacy strictly depend on internalization rate; GPI-anchored proteins exhibit distinct dynamics.
- Cross-species: Early screening with human, cynomolgus, and mouse orthologs is essential for translational safety.
- Stability: High-concentration formulations (>50 mg/mL) require low viscosity and aggregation testing.
TarMart supports these with high-purity ECD-Fc proteins, full-length lentivirus stable cell lines, clinical benchmark antibodies, and validated siRNA sets.